Ma Shuk-Woon, Benzie Iris F F, Yeung Vincent T F
Department of Health Technology & Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong.
Transl Res. 2008 Sep;152(3):134-42. doi: 10.1016/j.trsl.2008.07.003. Epub 2008 Aug 12.
The apolipoprotein E (APOE) epsilon2 allele is reported to be associated with greater risk of renal impairment in type 2 diabetes. Relationships among APOE polymorphisms, renal impairment, and biochemical parameters were explored. A prospective study of 405 consenting Chinese type 2 diabetic patients [mean age +/- standard deviation (SD): 59.2 +/- 10.3 years] without advanced complications at entry was conducted. APOE genotyping and measurement of plasma biomarkers of oxidative stress and antioxidants were performed at entry. HbA1C, plasma glucose, lipids, creatinine, urine albumin/creatinine, and blood pressure were measured at entry and at up to 4 years of follow-up. APOE allelic frequencies were in Hardy-Weinberg equilibrium. Odds ratios of albuminuria at entry and/or during follow-up for different APOE groups were not significantly different. The non-epsilon2 (epsilon3/3, epsilon3/4, epsilon4/4) group had significantly greater plasma ascorbate (51.6 +/- 20.1 mumol/L) than the epsilon2 (epsilon2/2, epsilon2/3) group (44.5 +/- 16.2 mumol/L, P = 0.021), but higher plasma ascorbate levels did not seem to decrease the risk of renal impairment in the non-epsilon2 group. Baseline plasma lipid-standardized alpha-tocopherol levels were least in epsilon2 subjects with persistent albuminuria (3.6 +/- 1.1 mumol/mmol of total cholesterol plus triglycerides, P = 0.008) compared with epsilon2 subjects who had no albuminuria at entry or during follow-up (4.5 +/- 0.8 mumol/mmol of total cholesterol plus triglycerides). The APOE epsilon2 allele does not seem to be associated with increased risk of renal impairment in Chinese type 2 diabetic patients. Plasma lipid-standardized alpha-tocopherol may play a role in determining risk of renal dysfunction in type 2 diabetes.
据报道,载脂蛋白E(APOE)ε2等位基因与2型糖尿病患者肾功能损害风险增加有关。本研究探讨了APOE基因多态性、肾功能损害和生化参数之间的关系。对405例入组时无晚期并发症的中国2型糖尿病患者进行了一项前瞻性研究[平均年龄±标准差(SD):59.2±10.3岁]。入组时进行了APOE基因分型以及氧化应激和抗氧化剂血浆生物标志物的测定。在入组时以及随访长达4年期间测量糖化血红蛋白(HbA1C)、血糖、血脂、肌酐、尿白蛋白/肌酐和血压。APOE等位基因频率处于哈迪-温伯格平衡。不同APOE组在入组时和/或随访期间蛋白尿的优势比无显著差异。非ε2(ε3/3、ε3/4、ε4/4)组的血浆抗坏血酸水平(51.6±20.1μmol/L)显著高于ε2(ε2/2、ε2/3)组(44.5±16.2μmol/L,P = 0.021),但较高的血浆抗坏血酸水平似乎并未降低非ε2组肾功能损害的风险。与入组时或随访期间无蛋白尿的ε2受试者相比,持续性蛋白尿的ε2受试者的基线血浆脂质标准化α-生育酚水平最低(总胆固醇加甘油三酯的3.6±1.1μmol/mmol,P = 0.008)。APOEε2等位基因似乎与中国2型糖尿病患者肾功能损害风险增加无关。血浆脂质标准化α-生育酚可能在决定2型糖尿病患者肾功能不全风险中起作用。